Clinical Trials · NCT05132088

Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity

CompletedPhase 3Semaglutide (Approved)
Phase
Phase 3
Recruitment status
Completed
Sponsor
Novo Nordisk A/S
Enrollment
201
Start date
Nov 2021
Locations
15 sites, Japan, South Korea
Primary endpoint
Percent Change From Baseline in Body Weight
View Semaglutide compound reference